Overview
Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect is an extremely rare genetic condition that affects newborns shortly after birth. This disease is caused by problems in the way the body's mitochondria — the tiny energy-producing structures inside every cell — handle a chemical process called methylation. Methylation is essential for mitochondria to work properly, including making the proteins needed to produce energy. When this process is disrupted, the heart and lungs are among the organs most severely affected because they require enormous amounts of energy to function. Babies born with this condition typically develop severe heart failure and breathing problems within the first days to weeks of life. The heart may become weak and enlarged, unable to pump blood effectively, while the lungs may fail to exchange oxygen properly. Other organs that need a lot of energy, such as the brain and liver, may also be affected. Symptoms can include difficulty breathing, poor feeding, low oxygen levels, bluish skin color, extreme fatigue, and failure to thrive. Unfortunately, the treatment landscape for this condition is very limited. Care is primarily supportive, focusing on helping the heart and lungs function as well as possible through intensive care measures. There are currently no approved curative treatments. Some mitochondrial supplements and cofactors may be tried, but their effectiveness in this specific condition has not been well established. Research into mitochondrial diseases is ongoing, and families are encouraged to connect with specialists in mitochondrial medicine for the most up-to-date guidance.
Also known as:
Key symptoms:
Severe heart failure in newbornsDifficulty breathing or respiratory failureBluish skin color due to low oxygenPoor feeding and inability to gain weightEnlarged and weakened heartLow energy and extreme fatigueLow blood oxygen levelsLiver problemsLactic acidosis (buildup of acid in the blood)Muscle weaknessFailure to thriveSwelling due to fluid buildupNeurological problems such as poor muscle tone
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect.
Community
No community posts yet. Be the first to share your experience with Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect.
Start the conversation →Latest news about Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect
No recent news articles for Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific gene mutation is causing my baby's condition, and what does it mean?,What is the expected course of this disease for my child?,Are there any experimental treatments or clinical trials that might help?,Should we consider mitochondrial supplements, and what evidence supports their use?,What is the chance of having another child with this condition, and what are our options for future pregnancies?,Can you connect us with a mitochondrial disease specialist or center of excellence?,What palliative care and family support services are available to us?
Common questions about Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect
What is Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect?
Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect is an extremely rare genetic condition that affects newborns shortly after birth. This disease is caused by problems in the way the body's mitochondria — the tiny energy-producing structures inside every cell — handle a chemical process called methylation. Methylation is essential for mitochondria to work properly, including making the proteins needed to produce energy. When this process is disrupted, the heart and lungs are among the organs most severely affected because they require enormous amounts of energy to
How is Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect inherited?
Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect typically begin?
Typical onset of Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect is neonatal. Age of onset can vary across affected individuals.